| Objective:Observe the effect of dexmedetomidine(DEX)on ischemia-reperfusion injury caused by tourniquet in diabetic patients during total knee arthroplasty,and determine whether DEX can reduce the remoteness myocardial damage caused by tourniquet in diabetic patients.Methods:In this study,80 patients with type 2 diabetes who underwent elective knee arthroplasty in ASAⅡ～Ⅲ grade and 50～70 years old were selected;they were divided into experimental group and control group.The experimental group was given DEX 1μg/kg 15 min intravenous pump before anesthesia.Intravenous pump injection at a constant rate of 0.5μg/kg·h to 30 minutes before the end of the operation,the control group was given the same amount of normal saline pump injection,respectively when entering the room(T0),30 minutes after the upper tourniquet(T1)、15minutes(T2)、 1 hour(T3)and 24 hours(T4)after the tourniquet was released,The concentration of venous blood was collected from the patient to detect SOD、MDA、IL-6、TNF-α、BNP、c Tn I,measure MAP、HR、SPO2 and blood glucose levels.Results:The levels of SOD、MDA、IL-6、TNF-α、BNP and c Tn I in the two groups of patients increased after the use of tourniquets,and the experimental group was significantly lower than the control group.The SOD levels of the two groups decreased after the use of tourniquets,but the experiment The group was significantly higher than the control group.After the tourniquet was used,the MAP 、 HR and blood glucose levels of the two groups were significantly lower than those of the control group,and the incidence of SPO2 and adverse reactions between the groups were not statistically significant(P>0.05).Conclusion: For patients undergoing total knee arthroplasty and type 2 diabetes,intraoperative application of dexmedetomidine can effectively reduce the impact of cardiac machine damage and oxidative stress on the patient,and can alleviate the increase in blood sugar caused by surgical stimulation and ensure the operation Security. |
